METTLER TOLEDO INTERNATIONAL INC（MTD）の決算・業績分析
METTLER TOLEDO INTERNATIONAL INCの2025年有価証券報告書をAI分析。売上高$4.0B(+4.0%)。Health Care。
目次
METTLER TOLEDO INTERNATIONAL INCの2025年度 業績サマリー
METTLER TOLEDO INTERNATIONAL INC（証券コード: MTD）の2025年度決算・業績分析。売上高は$4.0B（前年比+4.0%）。純利益は$869M（前年比+0.7%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
METTLER TOLEDO INTERNATIONAL INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 5.4% YoY to $3.9B (XBRL), with net income rising 13.5% YoY to $873M (XBRL).
- ROE reached 509.0% (XBRL), reflecting strong equity returns despite a low equity ratio of 4.9% (XBRL).
- Gross margin of 58.9% (XBRL) and operating margin of 30.4% (XBRL) highlight efficient cost management.
- Free cash flow of $738M (XBRL) supported by $1.1B in share repurchases (XBRL).
METTLER TOLEDO INTERNATIONAL INCの売上高変化の要因
- •FY2024 revenue of $3.9B (XBRL) reflects a 5.2% CAGR over five years (XBRL). Historical data shows steady growth from $2.9B in FY2020 to $3.9B in FY2024, though FY2025 revenue is projected at $3.8B (XBRL). Growth drivers include expansion in key markets and product innovation, though specific segment contributions are not disclosed (XBRL).
METTLER TOLEDO INTERNATIONAL INCの営業利益変化の要因
- •Profitability metrics include a 31.6% EBITDA margin ($1.2B, XBRL), 22.3% net margin ($873M, XBRL), and 30.4% operating margin ($1.2B, XBRL). Net income grew 13.5% YoY (XBRL), outpacing revenue growth. Gross margin of 58.9% (XBRL) underscores strong pricing power and cost control.
METTLER TOLEDO INTERNATIONAL INCの事業リスクと対応
Economic downturns in developed markets could reduce demand and impair cash flow (10-K).
Heavy reliance on China exposes the company to geopolitical tensions and trade restrictions (10-K).
International operations face currency volatility and legal changes (10-K).
Chinese real estate market challenges threaten sales and profitability (10-K).
Regulatory hurdles in China, including fund repatriation restrictions, complicate financial management (10-K).
$13.9M of cash in Chinese subsidiaries is at risk of nationalization (10-K).
METTLER TOLEDO INTERNATIONAL INCの事業内容
METTLER TOLEDO INTERNATIONAL INC (MTD) is a global leader in precision instruments and services, serving industries like life sciences, food, and chemicals (10-K). It generates revenue through the sale of laboratory balances, pipettes, analytical equipment (e.g., titrators, pH meters), and software solutions like LabX (10-K). The company operates in five reportable segments: U.S., Swiss, Western European, Chinese, and Other Operations (10-K). Competitive advantages include innovation leadership, a global sales/service network spanning 140+ countries, and strong market positions in most segments (10-K).
METTLER TOLEDO INTERNATIONAL INCのAI業績分析レポート（2024年度）
METTLER TOLEDO INTERNATIONAL INC (MTD) FY2024 Annual Report Analysis
Highlights
Business Overview
MTD is a global leader in precision instruments and services, serving industries like life sciences, food, and chemicals (10-K). It generates revenue through the sale of laboratory balances, pipettes, analytical equipment (e.g., titrators, pH meters), and software solutions like LabX (10-K). The company operates in five reportable segments: U.S., Swiss, Western European, Chinese, and Other Operations (10-K). Competitive advantages include innovation leadership, a global sales/service network spanning 140+ countries, and strong market positions in most segments (10-K).
Revenue Analysis
FY2024 revenue of $3.9B (XBRL) reflects a 5.2% CAGR over five years (XBRL). Historical data shows steady growth from $2.9B in FY2020 to $3.9B in FY2024, though FY2025 revenue is projected at $3.8B (XBRL). Growth drivers include expansion in key markets and product innovation, though specific segment contributions are not disclosed (XBRL).
Profitability Analysis
Profitability metrics include a 31.6% EBITDA margin ($1.2B, XBRL), 22.3% net margin ($873M, XBRL), and 30.4% operating margin ($1.2B, XBRL). Net income grew 13.5% YoY (XBRL), outpacing revenue growth. Gross margin of 58.9% (XBRL) underscores strong pricing power and cost control.
Balance Sheet Analysis
The company maintains a current ratio of 1.04x (XBRL), indicating modest liquidity. Total equity fell from $547M in FY2020 to $171M in FY2024 (XBRL), with long-term debt at $1.9B (XBRL). A debt-to-equity ratio of 20.45x (XBRL) highlights significant leverage, though asset turnover of 1.12x (XBRL) suggests efficient use of capital.
Cash Flow Analysis
Operating cash flow of $859M (XBRL) supported $738M in free cash flow after $121M in CapEx (XBRL). Financing activities included $1.1B in share repurchases (XBRL), offset by negative cash flows of $716M (XBRL). Capital expenditures were 3.1% of revenue (XBRL), with a CapEx/D&A ratio of 2.59x (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) of 78 days (XBRL) reflects 62 days of receivables, 36 days of inventory, and 20 days of payables (XBRL).
Risks
Outlook
N/A.
Health Careの企業一覧
METTLER TOLEDO INTERNATIONAL INCと同じ「Health Care」セクターの企業